AI trade rotation is not the end of the AI investment cycle

Conviction: 72% · Horizon: 2Y · 2026-07-08
Flows leaving headline AI names leave pure-play AI businesses mispriced

Broad de-risking from the AI narrative can drag down stocks whose economics are genuinely transformed by machine learning, underwriting automation, or AI-driven R&D. Select names with direct AI leverage can re-rate as fundamentals catch up while sentiment normalizes.

Instrument Side Target Reason
LMND Long Digital insurer built around data and algorithms can compound margins and growth as AI improves pricing, fraud detection, and customer acquisition faster than legacy carriers.
TEM Long Oncology diagnostics platform embedding AI in clinical workflows ties revenue to durable healthcare spend and benefits as models improve treatment matching and trial efficiency.
ABCL Long Antibody discovery partner using computational and ML workflows offers leveraged exposure to biopharma R&D productivity without single-drug binary risk at the platform level.

Themes

The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.